Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Change in Accured Expenses (2016 - 2025)

Rockwell Medical (RMTI) has disclosed Change in Accured Expenses for 16 consecutive years, with -$139000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 140.06% year-over-year to -$139000.0, compared with a TTM value of -$2.6 million through Sep 2025, down 2652.13%, and an annual FY2024 reading of -$1.0 million, down 175.0% over the prior year.
  • Change in Accured Expenses was -$139000.0 for Q3 2025 at Rockwell Medical, up from -$503000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.9 million in Q3 2023 and bottomed at -$3.3 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is -$64631.6, with a median of -$139000.0 recorded in 2025.
  • The sharpest move saw Change in Accured Expenses soared 600.0% in 2021, then plummeted 414.84% in 2023.
  • Year by year, Change in Accured Expenses stood at $777000.0 in 2021, then surged by 128.83% to $1.8 million in 2022, then crashed by 63.05% to $657000.0 in 2023, then tumbled by 143.07% to -$283000.0 in 2024, then surged by 50.88% to -$139000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for RMTI at -$139000.0 in Q3 2025, -$503000.0 in Q2 2025, and -$1.7 million in Q1 2025.